The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001
Related Experiment Video
Updated: Jul 6, 2026

Measurement of Lifespan in Drosophila melanogaster
Published on: January 7, 2013
1Graduate School of Business, Columbia University, National Bureau of Economic Research, 614 Uris Hall, 3022 Broadway, New York, NY 10027, USA. frank.lichtenberg@columbia.edu
Abstract:
We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Under conservative assumptions, our estimates imply that the average annual increase in life expectancy of the entire population resulting from new drug launches is about one week, and that the incremental cost effectiveness ratio (new drug expenditure per person per year divided by the increase in life-years per person per year attributable to new drug launches) is about $6750--far lower than most estimates of the value of a statistical life-year.
Related Concept Videos
Longitudinal Research
Clinical Trials: Overview
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacogenomics: Identification of New Drug Targets
Longitudinal Studies

